EGFR and metastatic colorectal cancer: Given this evidence, the KRAS mutation testing is approved by food and drug administration (FDA) for treatment of KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer, and is required by European medicines agency (EMA) before the initiation of anti-EGFR therapy.